DAVID C. HASTINGS

Insider Reports History

Location
Jersey City, NJ
Signature
/s/ Christopher Galletta, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by DAVID C. HASTINGS:

Company Role Class Num Shares Value Price $ Report Date Ownership
Arbutus Biopharma Corp Chief Financial Officer Common Shares 249,824 $820,172 $3.28 14 Feb 2025 Direct
SCYNEXIS INC Director Common Stock 69,183 $66,415 $0.9600 26 Jun 2025 Direct
Trevi Therapeutics, Inc. Chief Financial Officer Stock Option (right to buy) 375,000 08 Jan 2026 Direct
Arbutus Biopharma Corp Chief Financial Officer Stock Option (Right to Buy) 365,800 14 Feb 2025 Direct
SCYNEXIS INC Director Stock Option 23,000 26 Jun 2025 Direct
Entasis Therapeutics Holdings Inc. Director Common Stock 0 $2.20 11 Jul 2022 Direct
Entasis Therapeutics Holdings Inc. Director Stock Option (right to buy) 0 11 Jul 2022 Direct

Insider Reports Filed by DAVID C. HASTINGS

Symbol Company Period Transactions Value $ Form Type Role Filing Time
TRVI Trevi Therapeutics, Inc. 08 Jan 2026 1 $0 4 Chief Financial Officer 12 Jan 2026, 16:05
TRVI Trevi Therapeutics, Inc. 08 Jan 2026 0 $0 3 Chief Financial Officer 12 Jan 2026, 16:03
SCYX SCYNEXIS INC 26 Jun 2025 2 $0 4 Director 30 Jun 2025, 16:16
ABUS Arbutus Biopharma Corp 14 Feb 2025 2 $0 4 Chief Financial Officer 19 Feb 2025, 18:25
ABUS Arbutus Biopharma Corp 04 Feb 2025 1 -$72,827 4 Chief Financial Officer 05 Feb 2025, 16:02
SCYX SCYNEXIS INC 20 Jun 2024 2 $0 4 Director 21 Jun 2024, 16:10
ABUS Arbutus Biopharma Corp 01 Feb 2024 3 -$22,184 4 Chief Financial Officer 05 Feb 2024, 19:54
SCYX SCYNEXIS INC 15 Jun 2023 1 $0 4 Director 23 Jun 2023, 16:08
SCYX SCYNEXIS INC 15 Jun 2023 1 $0 4 Director 20 Jun 2023, 20:06
ABUS Arbutus Biopharma Corp 01 Feb 2023 2 $0 4 Chief Financial Officer 03 Feb 2023, 15:11
/report/000149315223000182-hastings-david-c-2023-01-01 Vascular Biogenics Ltd. 01 Jan 2023 0 $0 3 Director 03 Jan 2023, 20:04
/report/000110465922078789-hastings-david-c-2022-07-07 Entasis Therapeutics Holdings Inc. 07 Jul 2022 4 -$108,900 4 Director 11 Jul 2022, 16:05
SCYX SCYNEXIS INC 17 Jun 2022 2 $0 4 Director 22 Jun 2022, 16:06
ABUS Arbutus Biopharma Corp 20 Jan 2022 1 +$800,850 4 Chief Financial Officer 20 Jan 2022, 16:55
/report/000110465922005412-hastings-david-c-2022-01-18 Entasis Therapeutics Holdings Inc. 18 Jan 2022 1 $0 4 Director 19 Jan 2022, 15:01
/report/000110465922023768-hastings-david-c-2021-07-16 Entasis Therapeutics Holdings Inc. 16 Jul 2021 6 $0 4 Director 15 Feb 2022, 15:01
SCYX SCYNEXIS INC 16 Jun 2021 1 $0 4 Director 21 Jun 2021, 08:31